Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
Dow
Boehringer Ingelheim
Johnson and Johnson

Last Updated: March 22, 2023

SYMLIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Symlin, and what generic alternatives are available?

Symlin is a drug marketed by Astrazeneca Ab and is included in one NDA.

The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pramlintide acetate profile page.

Drug patent expirations by year for SYMLIN
Drug Prices for SYMLIN

See drug prices for SYMLIN

Recent Clinical Trials for SYMLIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute on Aging (NIA)Early Phase 1
Boston UniversityEarly Phase 1
H. Lee Moffitt Cancer Center and Research InstituteEarly Phase 1

See all SYMLIN clinical trials

US Patents and Regulatory Information for SYMLIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-002 Sep 25, 2007 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-003 Sep 25, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SYMLIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-002 Sep 25, 2007 See Plans and Pricing See Plans and Pricing
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 See Plans and Pricing See Plans and Pricing
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-002 Sep 25, 2007 See Plans and Pricing See Plans and Pricing
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 See Plans and Pricing See Plans and Pricing
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-001 Mar 16, 2005 See Plans and Pricing See Plans and Pricing
Astrazeneca Ab SYMLIN pramlintide acetate INJECTABLE;SUBCUTANEOUS 021332-003 Sep 25, 2007 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SYMLIN

See the table below for patents covering SYMLIN around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2130463 ANALOG-AGONIST OF AMYLINE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, COMPOSITION EXHIBITING PROPERTIES OF AMYLINE AGONIST See Plans and Pricing
Japan 2828250 See Plans and Pricing
Germany 69231583 See Plans and Pricing
Greece 3035287 See Plans and Pricing
European Patent Office 0529065 PROCEDES DE CRIBLAGE UTILISANT DES RECEPTEURS ET PERMETTANT LA DETECTION D'AGONISTES ET D'ANTAGONISTES DE L'AMYLINE (RECEPTOR-BASED SCREENING METHODS FOR AMYLIN AGONISTS AND ANTAGONISTS) See Plans and Pricing
Germany 69426304 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Medtronic
Moodys
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.